Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
<h4>Background</h4> <p>EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients w...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1797095790730018816 |
|---|---|
| author | Mentz, R Bethel, M Gustavson, S Thompson, V Pagidipati, N Buse, J Chan, J Iqbal, N Maggioni, A Marso, S Ohman, P Poulter, N Ramachandran, A Zinman, B Hernandez, A Holman, R |
| author_facet | Mentz, R Bethel, M Gustavson, S Thompson, V Pagidipati, N Buse, J Chan, J Iqbal, N Maggioni, A Marso, S Ohman, P Poulter, N Ramachandran, A Zinman, B Hernandez, A Holman, R |
| author_sort | Mentz, R |
| collection | OXFORD |
| description | <h4>Background</h4> <p>EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk</p> <h4>Methods</h4> <p>Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon-like peptide-1 receptor agonist (GLP-1RA) outcomes trials.</p> <h4>Results</h4> <p>A total of 14,752 participants randomized between June 2010 and September 2015, 6,788 (46.0%) patients were enrolled in Europe, 3,708 (25.1%) North America, 2,727 (18.5%) Latin America, and 1,529 (10.4%) Asia Pacific. Overall, 73% had at least one prior CV event (70% coronary artery disease, 24% peripheral arterial disease, 22% cerebrovascular disease). The median (IQR) age was 63 years (56, 69), 38% were female and 16% had a prior history of heart failure. Those without a prior CV event were younger with a shorter duration of diabetes and better renal function than those with at least one prior CV event. Compared with prior GLP-1RA trials, EXSCEL has a larger percentage of patients without a prior CV event and a notable percentage who were taking a dipeptidyl peptidase-4 inhibitor at baseline (15%).</p> <h4>Conclusions</h4> <p>EXSCEL is one of the largest global GLP-1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP-1RA trials</p> |
| first_indexed | 2024-03-07T04:32:58Z |
| format | Journal article |
| id | oxford-uuid:cef3e4f4-e0f6-462d-9513-d5642862ed87 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:32:58Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:cef3e4f4-e0f6-462d-9513-d5642862ed872022-03-27T07:39:11ZBaseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cef3e4f4-e0f6-462d-9513-d5642862ed87EnglishSymplectic Elements at OxfordElsevier2017Mentz, RBethel, MGustavson, SThompson, VPagidipati, NBuse, JChan, JIqbal, NMaggioni, AMarso, SOhman, PPoulter, NRamachandran, AZinman, BHernandez, AHolman, R <h4>Background</h4> <p>EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk</p> <h4>Methods</h4> <p>Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon-like peptide-1 receptor agonist (GLP-1RA) outcomes trials.</p> <h4>Results</h4> <p>A total of 14,752 participants randomized between June 2010 and September 2015, 6,788 (46.0%) patients were enrolled in Europe, 3,708 (25.1%) North America, 2,727 (18.5%) Latin America, and 1,529 (10.4%) Asia Pacific. Overall, 73% had at least one prior CV event (70% coronary artery disease, 24% peripheral arterial disease, 22% cerebrovascular disease). The median (IQR) age was 63 years (56, 69), 38% were female and 16% had a prior history of heart failure. Those without a prior CV event were younger with a shorter duration of diabetes and better renal function than those with at least one prior CV event. Compared with prior GLP-1RA trials, EXSCEL has a larger percentage of patients without a prior CV event and a notable percentage who were taking a dipeptidyl peptidase-4 inhibitor at baseline (15%).</p> <h4>Conclusions</h4> <p>EXSCEL is one of the largest global GLP-1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP-1RA trials</p> |
| spellingShingle | Mentz, R Bethel, M Gustavson, S Thompson, V Pagidipati, N Buse, J Chan, J Iqbal, N Maggioni, A Marso, S Ohman, P Poulter, N Ramachandran, A Zinman, B Hernandez, A Holman, R Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title_full | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title_fullStr | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title_full_unstemmed | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title_short | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). |
| title_sort | baseline characteristics of patients enrolled in the exenatide study of cardiovascular event lowering exscel |
| work_keys_str_mv | AT mentzr baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT bethelm baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT gustavsons baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT thompsonv baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT pagidipatin baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT busej baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT chanj baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT iqbaln baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT maggionia baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT marsos baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT ohmanp baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT poultern baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT ramachandrana baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT zinmanb baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT hernandeza baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel AT holmanr baselinecharacteristicsofpatientsenrolledintheexenatidestudyofcardiovasculareventloweringexscel |